Congress tests Medicaid coverage for rare skin disease wound care
H.R. 7877 — Shane DiGiovanna Act · Filed by Greg Landsman (D-OH) · 5 cosponsors · Introduced Mar 9, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires the federal government to run a 2-year nationwide test program making Medicaid cover specific wound-care supplies and over-the-counter medications for people with epidermolysis bullosa (a rare genetic skin disorder). The program covers items like antibiotic ointments, wound dressings, gauze, and pain relievers. After the test ends, the government must report to Congress on costs, health outcomes, and whether the coverage prevented hospitalizations.
Why we flagged it
The bill's operative mechanism is a straightforward expansion of Medicaid coverage for a specific patient population with a rare disease. It mandates inclusion of wound-care supplies and OTC medications in state Medicaid plans, with a built-in evaluation to assess outcomes and costs.
What the text implies
- The nationwide scope means all state Medicaid programs must comply, creating uniform coverage standards across states that may vary in their current wound-care policies for EB patients.
- The 2-year demonstration period creates a time-limited test; if successful, Congress would need separate legislation to make the coverage permanent, creating uncertainty for patients after the program ends.
The full analysis lists 4 implications of this text.
Who stands to gain
Patients with epidermolysis bullosa (reduced out-of-pocket costs); Wound-care supply manufacturers and distributors (increased demand via Medicaid coverage)